Purpose: To determine if online medical education for diabetologists/endocrinologists (diabs/endos) and primary care physicians (PCPs) can improve knowledge regarding the consequences of elevated PPG, the need for better PPG control and more physiologic mealtime insulin replacement, PK/PD profiles, and latest clinical data of investigational faster-acting insulin analogs.

Methods: The educational activity consisted of a 30-min online video panel discussion amongst four experts with synchronized slides. Educational effect was assessed with a repeated pairs pre- and post-assessment study using a 3-item, multiple-choice, knowledge and competence questionnaire plus a confidence assessment in which participants act as their own controls. A χi-squared test assessed statistical significance at the P <.level. The activity launched December 21, 2016; data collected until February 1, 2017.

Results: Participation in the activity significantly improved knowledge of diabs/endos (average from 47% to 69%; n=73) and PCPs (from 55% to 72%; n=112) with respect to latest clinical data and potential benefits of new and emerging faster-acting insulins. On pre-assessment, clinicians showed high levels of knowledge (87%/82%) about the consequences of elevated PPG which was primarily reinforced on post-assessment. After participation, 51% of diabs/endos and 67% of PCPs demonstrated greater confidence in their understanding of the clinical profile of emerging faster-acting insulins for PPG management.

Conclusions: Participation in online education resulted in improvement or reinforcement of knowledge and confidence regarding the importance of good PPG control and the clinical profile of investigational faster-acting insulins. Further education is warranted on complications that correlate with elevated PPG, physiologic action of mealtime insulin replacement and latest clinical data of new and emerging faster-acting insulins.


A.M. Sendaydiego: None. J. Trier: None. E. Montanya: Employee; Spouse/Partner; Almirall, S.A.. Advisory Panel; Self; AstraZeneca. Consultant; Self; Intarcia Therapeutics, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Research Support; Self; Menarini Group. Consultant; Self; MSD K.K.. Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S, AstraZeneca, Medscape. Advisory Panel; Self; Servier. Speaker's Bureau; Self; Servier. Consultant; Self; Novartis Pharmaceuticals Corporation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.